Remedy: Towards the AW2 release in a cautiously positive mood

Av Atte Riikola
There were no major surprises in the company's Q4 figures and, as expected, the outlook for 2023 is still weak in light of the figures. This year, Remedy is still clearly in an investment phase as the company builds its strategy for the next growth leap with 5 major gaming projects under development. However, the company's investment story is already entering an interesting phase at the end of the year with the release of Alan Wake 2, which will also be a key short-term driver for the stock. At the current share valuation, we are moving towards the release of the game in a cautiously positive mood.